About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT01410552

Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination

ISIS- ICD study has been designed to evaluate the impact of PARAD+ algorithm on inappropriate shocks, in a general population implanted for primary or secondary prevention with a dual or tri chamber d...

Lead sponsor: MicroPort CRM•27 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

MicroPort CRM

The primary endpoint is to demonstrate that 95% of patients implanted with PARAD+ algorithm are free from inapproporiate shock compared to 92.5% in general ICD population.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patient eligible for implantation (according to current accepted guidelines, or scheduled for implant (primo-implant, replacement, upgrade) with a Paradym/Paradym RF (CRT-D or DR-ICD) within the next 30 days, or has already been implanted within the last 30 days
•2. Patient in sinus rhythm, or patients with paroxysmal atrial tachyarrhythmia or patients with persistent atrial tachyarrhythmia in whom a cardioversion is planned within three months

Exclusion Criteria

•1. Any contraindication for ICD therapy
•2. Atrial lead not implanted
•3. Patient with permanent atrial tachyarrhythmia
•4. Patients implanted with a ventricular assist device (VAD)

Related studies

Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation

NCT07201506 · Ablation of Arrhythmias, Premature Ventricular Contractions, and more

DEEP Substrate Mapping Versus Activation Mapping for VT

NCT06371729 · Ventricular Tachycardia

RECRUITINGPhase 1

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

NCT07148089 · Catecholaminergic Polymorphic Ventricular Tachycardia

Cohort Study - SBRT for VT Radioablation

NCT04162171 · Ventricular Tachycardia, Myocardial Infarction, and more

RECRUITINGPhase 2

A Study of Pyridostigmine in Postural Tachycardia Syndrome

NCT00409435 · Postural Tachycardia Syndrome

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 22, 2019Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment1,013

Start dateOct 2011

Last updatedMar 22, 2019

Condition

Locations shown

Southwest Cardiovascular Associates

Mesa, Arizona

Pacific Arrhythmia Services

Mesa, Arizona

Banner Arizona Medical Clinic

Peoria, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 22, 2019Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions